The approval of the covid-19 vaccine developed by Pfizer with its German partner BioNTech SE comes at a time when the US is facing a rise in infections due to the spread of the Delta variant. Investors also cheered other positive announcements from Pfizer, including a major acquisition and approval for another drug.